Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes
Lawrence Chang(University of Michigan), Sung Won Choi(University of Michigan), David Frame(Rush University), James L.M. Ferrara(Tisch Hospital), Kathryn Schultz(Rush University Medical Center), David A. Hanauer(Associated Press), John E. Levine(Icahn School of Medicine at Mount Sinai), Sophie Paczesny(MUSC Hollings Cancer Center), Erin Gatza(Pediatrics and Genetics), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Pavan Reddy(Wichita State University), John Magenau(University of Michigan), Thomas Braun(University of Michigan), Hemasri Tokala(Michigan State University)
Cited by 91
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
|Frontiers in Immunology|2017|612
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
|Clinical Infectious Diseases|2020|501
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
|Biology of Blood and Marrow Transplantation|2005|458